|
|
| | H-GLN-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-ALA-OH Basic information |
| Product Name: | H-GLN-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-ALA-OH | | Synonyms: | QRPRLSHKGPMPA;[ALA13]-APELIN-13;(ALA13)-APELIN-13 (HUMAN, BOVINE, MOUSE, RAT);(Ala13)-Apelin-13 (human, bovine, mouse, rat) trifluoroacetate salt H-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala-OH trifluoroacetate salt;(Ala13)-Apelin-13 (human, bovine, mouse, rat) acetate salt H-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala-OH acetate salt;H-GLN-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-ALA-OH;[Ala13]Apelin-13, human, bovine, mouse, rat (F13A) (2);[Ala13]Apelin 13 (human, mouse, rat, bovine) | | CAS: | 568565-11-7 | | MF: | C63H107N23O16S | | MW: | 1474.73 | | EINECS: | | | Product Categories: | peptide;Apelin receptor | | Mol File: | 568565-11-7.mol |  |
| | H-GLN-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-ALA-OH Chemical Properties |
| density | 1.52±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | pka | 3.70±0.10(Predicted) | | form | powder | | color | white to beige | | Sequence | Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | H-GLN-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-ALA-OH Usage And Synthesis |
| Uses | (Ala13)-Apelin-13 is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 inhibits gastric motility through vagal cholinergic pathway[1]. | | Biological Activity | (Ala13)-Apelin-13 corresponds to Apelin-13 with a Phe-to-Ala substitution at the C-terminus (F13A) and functions as an antagonist against apelin-dependent APJ functions both in cultures and in animal studies in vivo. | | in vivo | (Ala13)-Apelin-13 (1-300 pmol/60 nl; microinjected into the DVC) decreases gastric tone and motility in a dose-dependent manner in rats[1]. | Animal Model: | 250-300 g, Sprague-Dawley rats[1] | | Dosage: | 1-300 pmol/60 nl | | Administration: | Microinjected into the DVC (dorsal vagal complex (DVC) | | Result: | Decreased gastric tone and motility in a dose-dependent manner with D50≈27 pmol for both antrum and corpus. |
| | References | [1] Bülbül M, et al. Apelin-13 inhibits gastric motility through vagal cholinergic pathway in rats. Am J Physiol Gastrointest Liver Physiol. 2018 Feb 1;314(2):G201-G210. DOI:10.1152/ajpgi.00223.2017
[2] O'Harte FPM,et al. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. Biochem Pharmacol. 2017 Dec 15;146:165-173. DOI:10.1016/j.bcp.2017.10.002 |
| | H-GLN-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-ALA-OH Preparation Products And Raw materials |
|